BASF stock edges lower as patent lawsuit against Apple draws attention

BASF stock trades slightly weaker on Xetra as investors weigh a new patent lawsuit against Apple and the broader chemicals backdrop in Germany.

BASF (ISIN DE000BASF111) stock traded at 53.41 EUR on Xetra on September 4, 2026, marking a modest intraday decline of 0.2 percent as investors digested a fresh patent lawsuit against Apple and the chemicals sector backdrop in Germany.

Patent dispute with Apple comes into focus

According to a report by Investing.com dated September 3, 2026, BASF has filed a complaint in the U.S. District Court in Midland, Texas, accusing Apple of infringing its patented face authentication technology in dozens of iPhone and iPad models.

The lawsuit, also highlighted in a brief market note compiled by Newsquawk on September 4, 2026, adds a new angle to BASF's technology portfolio, which extends beyond traditional chemicals into advanced materials and digital applications.

Stock performance and market data

Market data from Finanzen.ch show that BASF shares were down around 0.2 percent at 53.41 EUR on Xetra at 16:29 on September 4, 2026, after starting the trading day at 53.01 EUR.

A separate performance overview compiled by MarketScreener indicates that BASF closed the previous Xetra session on September 3, 2026 at 53.51 EUR, with a 5 day performance of approximately 3.3 percent and a year to date gain of about 20.4 percent.

That means the current price of 53.41 EUR on September 4, 2026 stands 0.1 EUR below the prior Xetra close of 53.51 EUR, while still reflecting a clearly positive performance versus the level observed at the beginning of the year, as described in the MarketScreener overview.

Analyst view and sector backdrop

For investors following the global listing, the American depositary receipt BASFY carries a consensus rating of Moderate Buy, based on nine analyst recommendations compiled by MarketBeat as of early September 2026.

Within this group, one analyst has issued a sell rating, three have assigned hold ratings, four recommend buying the shares and one has a strong buy rating, illustrating a broadly constructive but differentiated view on BASF's prospects.

In parallel, the broader German chemicals and pharmaceuticals industry posted a rebound in the second quarter of 2026; data released by the German Chemical Industry Association VCI and summarized by Echemi on September 4, 2026 indicate that production increased 2.4 percent quarter on quarter in Q2 2026, while sales rose 7.3 percent to 54.5 billion EUR.

This sector recovery provides an important backdrop for BASF, which remains one of the largest constituents of the German chemicals space and a key player in the DAX environment, even as it seeks to balance cyclical demand, energy costs and investments in higher margin specialty segments.

Representative product and specialty chemicals angle

Alongside its legal and market developments, BASF continues to invest in specialty chemicals capacity; a recent industry update on Echemi highlights that BASF has raised capacity for acid chloride and chloroformate products by around 30 percent at a European facility, underlining the group’s focus on higher value intermediates for pharmaceuticals, agrochemicals and coatings.

Stock price and investor takeaway

On September 4, 2026, BASF stock last traded at 53.41 EUR on Xetra, down 0.2 percent on the day but still supported by a year to date gain of more than 20 percent, with the patent lawsuit against Apple adding a new, potentially value relevant dimension to the investment case for long term shareholders.

BASF stock key data

• Company: BASF SE
• ISIN: DE000BASF111
• WKN: BASF11
• Ticker: BAS
• Trading venue: Xetra
• Price (as of September 4, 2026, 16:29): 53.41 EUR
• Sector / Industry: Chemicals
• Index membership: DAX